The Pathologic Response of the Liver and Thyroid of the Rat to Potassium Prorenoate (SC-23992)

Abstract

A 3-month dose range finding study in preparation for a 2-yr carcinogenicity study of potassium prorenoate (SC-23992), a steroid with an antihypertensive profile, is reported. The drug was administered by gavage once daily at doses of 10, 30, and 100 mg/kg/day to Charles River CD rats. Treatment was terminated at 13 weeks and 10 randomly selected animals from each treatment group were killed and necropsied. The remaining 10 animals in each dose group, including controls, were maintained for an additional 4 weeks, in order to investigate reversibility of changes, and then were killed and necropsied. Dose-related increases in thyroid-stimulating hormone (TSH) levels were observed in treated animals of both sexes during the dosing period and the changes were statistically significant and correlated with an increased thyroid weight in females at 13 weeks. Dose-related morphologic changes in the thyroid, observed by light and electron microscopy, were compatible with the effects of TSH stimulation. Liver weights, which increased, were dose-related. In females the increase was statistically significant at the high dose at 2, 4, and 13 weeks. In males it was significant at the high dose at 13 weeks. Microsomal enzyme levels were increased in a time- and dose-related manner with higher values in females than in males. The pattern of enzyme induction was of the type exemplified by pregnenolone-16-α-carbonitrile. Morphologic changes in the liver showed centrilobular hepatocyte enlargement with smooth endoplasmic reticulum membrane proliferation confirmed by electron microscopy. All positive findings returned to normal after the 4-week treatment-free period. The relationship between the thyroid stimulation to liver enzyme induction is of interest. Evidence is presented here that in the presence of SC-23992, TSH stimulation and liver enzyme induction occurred. The possibility that the liver metabolism stimulates the thyroid T₃, T₄ elimination with secondary TSH activity is a possible explanation, but on the basis of existing information, direct action by SC-23992 on the thyroid cannot be excluded.

References

1. Akoso BT , Sleight SD , Nachreincr RF , and Aust SD (1982). Effects of purified polybrominated biphenyl cogeners on the thyroid and pituitary in rats. J. Am. Coll. Toxicol. 3:23–36.

2. Andress JM (1976). SC 23992: Acute single dose toxicity in rats, mice and dogs, SA 1255. Unpublished report, Department of Product Safety Assessment, G. D. Searle & Co., Skokie, IL.

3. Bastomsky CH (1977). Enhanced thyroxine metabolism and high uptake goiters in rats after a single dose of 2,3,7,8-tetrachlorodibenzo-p-dioxin. Endocrinology 101:292–296.

4. Bernstein G , Artz SA , Hasen J , and Oppenheimer JH (1968). Hepatic accumulation of I-125-thyroxine in the rat: Augmentation by phenobarbital and chlordane. Endocrinology 82: 406.

5. Comer CP , Chengelis CP , Levin S , and Kotsonis FN (1986). Changes in thyroidal function and liver UDP-glucuronosyltransferase activity in rats following administration of novel imidazole (SC-37211). Toxicol. Appl. Pharmacol., in press.

6. Fang VS and Refetoff S (1974). Radioimmunoassay for serum triiodothyronine (T3); evaluation of simple technique to control interference from binding proteins. Clin. Chem. 20:1150–1157.

7. Lim VS , Henriquez C , Seo H , Refetoff S , and Martino R (1980). Thyroid function in a uremic rat model. J. Clin. Invest. 66:946–954.

8. Lissitsky S (1976). Biosynthesis of thyroid hormones. Pharmacol. Ther. B 2:219–246.

9. Lucier GW , McDaniel OS , and Hook GER (1975). Nature of the enhancement of hepatic uridine diphosphate glucuronyl transferase activity by 2,3,7,8-tetrachlorodibenzo-p-dioxin in rats. Biochem. Pharmacol. 24:325–334.

10.

10. Lumb G, Bernard BK, Semler DE, Lin LY, Pool WR, Dodd DC, and Klimstra PD (1980). Thirteen week oral toxicity study of SC-23992 in the rat, SA 1451. Unpublished report, Department of Product Safety Assessment, G. D. Searle & Co., Skokie, IL.

11.

11. Lumb G , Newberne P , Rust JH , and Wagner B (1978). Effects in animals of chronic administration of spironolactone—A review. J. Environ. Pathol. Toxicol. 1:641–660.

12.

12. Martinez TB (1972). SC 23992: Acute toxicity studies in the mouse and rat, SA 1401. Unpublished report. Department of Product Safety Assessment, G. D. Searle & Co., Skokie, IL.

13.

13. Ohnhaus EE and Studer H (1983). A link between liver microsomal activity and thyroid hormone metabolism in man. Br. J. Clin. Pharmacol. 15:17–76.

14.

14. Pastan I , Roth J , and Macchia V (1966). Binding of hormone to tissue: the first step in polypeptide hormone action. Proc Natl. Acad. Sci. U. S. A. 56:1802–1809.

15.

15. Poland A and Glover E (1973). Chlorinated dibenzo-p-dioxins: Potent inducers of aminolevulinic acid synthesase and aryl hydrocarbon hydroxylase. II. A study of the structure-activity relationship. Mol. Pharmacol. 9:736–747.

16.

16. Reichlin S , Martin JB , Boshaus RL , Schalch DS , Pierce JG , and Bollinger J (1971). Measurement of TSH in plasma and pituitary of the rat by a radioimmunoassay utilizing bovine TSH: Effect of thyroidectomy or thyroxine administration on plasma TSH levels. Endocrinology 87:1022–1031.

17.

17. Rowlands ACF , Castracane VD , Hamilton MG , and Seifter J (1981). Effect of polybrominated biphenyls (PBB) on the pituitary-thyroid axis (41099). Proc. Soc. Exp. Biol. Med. 166:506–514.

18.

18. Seo H , Refetoff S , and Fang VS (1977). Induction of hypothyroidism and hypoprolactinemia by growth hormone producing rat pituitary tumors. Endocrinology 100:216–226.

19.

19. Youkilis GJ, Hemm RD, Martinez TB, and Sameta K (1972). SC-23992: Four week oral toxicity study in the rat, 971S71. Unpublished report, Department of Product Safety Assessment, G. D. Searle & Co., Skokie, IL.